Cite

HARVARD Citation

    White, W. et al. (n.d.). Cardiovascular safety of the dipetidyl peptidase‐4 inhibitor alogliptin in type 2 diabetes mellitus1. Diabetes, obesity & metabolism. 15 (7), pp. 668-673. [Online]. 
  
Back to record